Trellus Health PLC shares surged on Tuesday after the company announced a collaboration with Johnson & Johnson Health Care Systems Inc to integrate its Trellus Elevate platform into a patient support programme in the US.
The London-based healthcare company said the agreement will support a pilot program to assess Trellus Elevate’s ability to assist patients with moderately to severely active inflammatory bowel disease. Trellus will receive an undisclosed upfront licensing fee and a fixed monthly fee for managing the program.
Shares in Trellus multiplied to 2.92 pence in London on Tuesday afternoon. The stock had closed at 0.60 pence on Monday. Johnson & Johnson shares were 0.2% lower in pre-market trading at $144.25 each on Tuesday in New York.
Eligible patients prescribed a Johnson & Johnson therapy will gain access to Trellus Elevate, a digital platform combining data analytics with personalised resilience programs to help manage chronic conditions.
Trellus Chief Executive Officer Marla Dubinsky said: ‘We identified the pharmaceutical sector as a key strategic vertical in our September interim results and are excited to announce our first major collaboration in this vertical.’
Copyright 2025 Alliance News Ltd. All Rights reserved.
